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Gender- and Race-Specific Metabolic Score and
Cardiovascular Disease Mortality in Adults:
A Structural Equation Modeling Approach—United States,
1988-2006
Carla I. Mercado1, Quanhe Yang1, Earl S. Ford2, Edward Gregg3 and Amy L. Valderrama4

Objective: Consider all metabolic syndrome (MetS) components [systolic (SBP) and diastolic (DBP) blood
pressures, waist circumference, HDL cholesterol, triglycerides (TG), and fasting glucose] and gender/race
differential risk when assessing cardiovascular disease (CVD) risk.
Methods: We estimated a gender- and race-specific continuous MetS score using structural equation
modeling and tested its association with CVD mortality using data from National Health and Nutrition
Examination Survey III linked with the National Death Index. Cox proportional hazard regression tested
the association adjusted for sociodemographic and behavior characteristics.
Results: For men, continuous MetS components associated with CVD mortality were SBP (hazard
ratio 5 1.50, 95% confidence interval 5 1.14-1.96), DBP (1.48, 1.16-1.90), and TG (1.15, 1.12-1.16). In
women, SBP (1.44, 1.27-1.63) and DBP (1.24, 1.02-1.51) were associated with CVD mortality. MetS score
was not significantly associated with CVD mortality in men; but significant associations were found for all
women (1.34, 1.06-1.68), non-Hispanic white women (1.29, 1.01-1.64), non-Hispanic black women (2.03,
1.12-3.69), and Mexican-American women (3.57, 2.21-5.76). Goodness-of-fit and concordance were overall better for models with the MetS score than MetS (yes/no).
Conclusions: When assessing CVD mortality risk, MetS score provided additional information than MetS
(yes/no).
Obesity (2015) 23, 1911-1919. doi:10.1002/oby.21171

Introduction
Cardiovascular disease (CVD) is the leading cause of death in the
US and worldwide (1). A cluster of risk factors commonly found
among individuals with CVD (dyslipidemia, hypertension, hyperglycemia, and excess abdominal fat) led to the development of a condition known as metabolic syndrome (MetS) (2). Most recently, a
harmonized MetS definition was presented as having abnormal
values for three of the five metabolic components: blood pressure,
fasting glucose, waist circumference, HDL cholesterol, or triglycerides (3), based on established cut points.

Although MetS predicts CVD events (4,5), there are some major
limitations to the most recent harmonized definition of MetS (3).
First, the established cut points of each metabolic component may
not be most effective in predicting CVD risk for certain subgroups
or populations. One example is the MetS paradox among AfricanAmericans who have greater prevalence of hypertension and better
cholesterol profiles than other races/ethnicities (6,7), and cut points
may need to be adapted to identify early CVD risk. Additionally,
the current MetS definition does not distinguish between which
components are present, and there may be interaction between combinations of components that result in greater CVD risk than others.
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Additional limitations raised by a joint statement from the American
Diabetes Association and the European Association for the Study of
Diabetes includes ill-defined cut points with possible loss of information, lack of basis for the inclusion or exclusion of other CVD
risk factors, and treatment of MetS is no different than the treatment
of its components (8). Overall, the medical value of diagnosing
MetS was questioned. However, CVD events and mortality have
been found to be driven by MetS independently from the components (9). Additionally, individuals with MetS are at increased risk
of CVD mortality and all-cause mortality compared with those without MetS (10-13). Even though these studies have consistently found
a positive relationship between MetS and CVD mortality, MetS is
criticized due to limitations of the definition (yes/no) and the inflexibility of evaluating abnormal MetS components differently for race
and gender subgroups.

MetS was based on the latest harmonized definition of having three
or more abnormal values of any of the following components: blood
pressure, fasting glucose, waist circumference, HDL cholesterol, and
triglycerides (3). Presence of the blood pressure component was a
systolic blood pressure 130 mm Hg, diastolic blood pressure
85 mm Hg, or prescribed medication use for high blood pressure.
Abnormal fasting glucose was defined as 100 mg/dl or the use of
glucose altering medication (insulin/diabetic pills). Gender-specific
cut points were specified for waist circumference (men: 102 cm
and women: 88 cm) and HDL cholesterol components (men:
<40 mg/dl and women: <50 mg/dl). Abnormal triglycerides were
150 mg/dl. Participants meeting three or more of these criteria
were categorized as having MetS.

Statistical analysis
Even though the harmonized definition has provided country- and
gender-specific cut points for a couple of components, ideally we
would use the measured value of each component when assessing
CVD risk while acknowledging differential risk among certain populations. In this study, we tested independent associations between
each metabolic component and CVD mortality. Then, we used a
method that addresses the limitations of MetS by estimating an individual continuous MetS score based on the actual value of all components and tested its association with CVD mortality.

Methods
Study population
Data from the National Health and Nutrition Examination Survey III
(NHANES III) was used where participants were selected from a
complex, multistage, probability sampling design to represent the
non-institutionalized US population (14). NHANES III was conducted from 1988 to 1994 and contains data on 19,288 nonpregnant
adults aged 18 years or older. Data on participants from NHANES
III were linked to death certificates from the National Death Index
to obtain mortality status through December 31, 2006 (15). CVD
mortality was classified as cause of death from Major Cardiovascular Diseases or ICD-10 codes of I00 to I78.
Of the 19,288 nonpregnant adults, 25 were ineligible for mortality
linkage resulting in a remaining 19,263 participants. Participants
were then excluded if there were: no fasting lab data available (n =
11,157); no measurements for blood pressure (n = 2345) or anthropometric (n = 3154); medical history of cancer (n = 775), heart failure
(n = 747), stroke (n = 646), or heart attack (n = 932); or missing
covariate data (n = 772). These numbers are not mutually exclusive
and 5759 participants remained in this study. Morning sample
weights, also known as fasting weights, were used to account for
non-response due to not fasting or missing laboratory data.

Measurements
Participants underwent interviews and detailed physical exams.
Waist circumference was measured to the nearest 0.1 cm from the
top of the iliac crest with the tape measure parallel to the floor.
Blood pressure was determined based on an average of three blood
pressure measurements. Blood samples were collected to obtain
measures of plasma glucose and lipid profiles (HDL cholesterol and
triglycerides).
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All analyses used sampling weights and adjusted variance estimates
to account for the complex sampling design. Demographic characteristics were described as count and percent for discrete variable and
mean with standard errors for continuous variables. Structural equation modeling, a statistical estimation method, was used to calculate a
metabolic score for each participant based on the values of the following metabolic components: systolic blood pressure, diastolic
blood pressure, fasting glucose, waist circumference, HDL cholesterol, and triglycerides. During the estimation process, correlated
errors were specified between systolic and diastolic blood pressure
measures as well as between HDL cholesterol and triglycerides due
to the relationship these variables have with each other. For the purpose of comparing components’ contribution to the metabolic score,
factor loadings were standardized based on the variance of the fitted
model. Because gender and race/ethnic differences in the distribution
of some of these components may exist, path diagrams were estimated separately for each gender-race subgroup, and differences were
tested using Score and Wald tests. Goodness-of-fit of the specified
path diagrams were assessed by the standardized root mean squared
residuals (SRMR; good fit 0.08) and by the coefficient of determination (CD; good fit >0.56 which is equivalent to an R2 of 0.75).
Cox proportional hazards regression analysis was used to test the
association between time to CVD death in five ways: (1) each continuous metabolic component independently, (2) harmonized MetS
(yes/no), (3) the number of metabolic components present based on
harmonized cut points and (4) the metabolic score calculated from
structural equation modeling. When testing the independent association between CVD mortality and each metabolic component, components were standardized to have a distribution of mean zero and a
standard deviation of one for the purpose of coefficient comparison
across models. Meaning, the greatest coefficient with significance
would be considered a more important predictor. Person-time used
in these analyses was the date from the NHANES in-person exam to
the day of death or December 31, 2006 for those assumed alive.
Since metabolic scores are gender and race specific, hazard ratios
were stratified by gender and race/ethnicity. Models were adjusted
for: age (years), education (highest grade or year of school completed), physical activity [active (moderated physical activity 5
times per week or vigorous physical activity 3 times per week) or
inactive], smoking status (never, former, or current), alcohol consumption (none, less than three drinks per week, or three or more
per week), and self-reported medication use for hypertension, diabetes, or high cholesterol. Statistical significance was denoted as P
value less than 0.05.
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Age group (years)
18-44
45-64
65
Education (respondents
aged 25 years)
<High school diploma
High school diploma
Some college
College degree
Smoking statusb
Current
Former
Never
Alcohol consumption
categoriesc
None
<3 drinks per week
3 drinks per week
Physical activityd
Active
Inactive
Medication use fore:
High cholesterol
Hypertension
Diabetes
Metabolic syndrome
(harmonized
definition)f

United States
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31.5 (29.4-33.6)
32.1 (29.2-35.0)
36.4 (33.6-39.2)

30.6 (25.9-35.2)
25.5 (22.6-28.4)
43.9 (39.9-47.9)
48.1 (44.0-52.2)
51.9 (47.8-56.0)
2.3 (1.6-3.0)
8.2 (6.7-9.7)
2.8 (2.0-3.7)
28.4 (25.0-31.8)

28.8 (26.8-30.8)
26.4 (24.6-28.2)
44.8 (43.0-46.6)

41.6 (37.9-45.2)
26.7 (24.3-29.1)
31.8 (29.1-34.5)
44.2 (40.9-47.4)
55.8 (52.6-59.1)
2.5 (1.9-3.1)
10.3 (9.1-11.6)
2.4 (1.8-3.0)
27.3 (25.2-29.3)

(18.7-24.9)
(27.7-33.8)
(18.2-25.0)
(22.7-29.1)

21.8
30.8
21.6
25.9

20.9
34.1
21.6
23.3

(18.6-23.2)
(31.8-36.5)
(19.4-23.9)
(20.9-25.8)

62.3 (59.1-65.6)
26.6 (24.1-29.0)
11.1 (9.5-12.7)

Men
(N = 2721),
% (95% CI)

59.5 (56.4-62.6)
27.6 (25.2-29.9)
12.9 (11.4-14.4)

All
(N = 5759),
% (95% CI)

(17.9-22.3)
(34.2-40.3)
(18.6-24.8)
(18.2-23.8)

2.7 (1.8-3.5)
12.3 (10.7-13.9)
2.0 (1.4-2.7)
26.2 (23.6-28.8)

40.5 (36.7-44.2)
59.5 (55.8-63.3)

51.9 (48.1-55.8)
27.7 (24.3-31.2)
20.4 (17.4-23.3)

26.3 (23.2-29.3)
21.1 (18.8-23.3)
52.6 (49.9-55.4)

20.1
37.2
21.7
21.0

56.8 (53.1-60.5)
28.6 (25.5-31.6)
14.6 (12.7-16.6)

Women
(N = 3038),
% (95% CI)

(15.0-20.1)
(31.7-37.1)
(19.9-24.9)
(23.0-28.4)

2.7 (1.9-3.4)
10.2 (8.7-11.6)
2.2 (1.5-2.9)
27.7 (25.3-30.2)

45.4 (41.8-49.1)
54.6 (50.9-58.2)

39.7 (35.5-44.0)
27.6 (24.8-30.4)
32.7 (29.5-35.9)

28.6 (26.2-31.1)
28.4 (26.4-30.3)
43.0 (40.9-45.1)

17.5
34.4
22.4
25.7

57.1 (53.5-60.8)
28.9 (26.1-31.7)
14.0 (12.3-15.7)

Non-Hispanic
white (N = 2444),
% (95% CI)

(26.2-32.3)
(33.2-41.0)
(17.4-23.0)
(10.8-16.0)

1.8 (1.2-2.4)
13.9 (11.5-16.3)
3.9 (3.0-4.8)
22.1 (19.9-24.2)

40.9 (37.9-44.0)
59.1 (56.0-62.1)

52.8 (50.2-55.4)
21.1 (19.0-23.1)
26.2 (24.0-28.4)

33.1 (30.3-35.9)
16.0 (13.3-18.7)
50.9 (47.3-54.4)

29.3
37.1
20.2
13.4

68.8 (65.5-72.1)
22.5 (19.6-25.5)
8.7 (7.1-10.3)

Non-Hispanic
black (N = 1664),
% (95% CI)

1.0 (0.5-1.4)
5.5 (4.3-6.6)
3.1 (2.3-3.9)
30.7 (27.7-33.6)

31.9 (27.9-35.9)
68.1 (64.1-72.1)

46.6 (42.4-50.7)
24.3 (20.8-27.7)
29.2 (26.2-32.2)

22.5 (19.4-25.7)
18.6 (15.6-21.5)
58.9 (55.5-62.3)

58.5 (55.3-61.7)
23.3 (20.3-26.3)
12.3 (9.3-15.4)
5.9 (4.2-7.6)

76.0 (72.7-79.4)
18.5 (15.6-21.4)
5.5 (4.5-6.4)

Mexican-American
(N = 1651),
% (95% CI)

TABLE 1 Prevalence of characteristics among adults aged 18 yearsa and by sex and race/ethnicity—National Health and Nutrition Examination Survey III,
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Participants were excluded if they were: pregnant women; missing anthropometric, laboratory, or blood pressure measurements; fasting less than 8 h; or medical history of cancer (all cancers except skin cancer) or
CVD (coronary heart disease, heart attack, or stroke).
Smoking status defined as: current smokers (self-reported current smoker), former smoker (1001 cigarettes in lifetime and not current smoker), and never smoker (has not smoked 1001 cigarettes in lifetime and not
current smoker).
c
Alcohol consumption defined as first having at least 12 alcohol drinks in the past 12 months to distinguish between drinkers and nondrinkers. Among those who had at least 12 alcoholic drinks, an average number of
drinks per week was calculated and categorized as <3 or 3 drinks per week.
d
Physical activity was categorized as active or inactive. Active was defined as at least 30 min of: moderate physical activity at least five times per week or vigorous physical activity at least three times per week.
e
Self-reported medication use.
f
Metabolic syndrome NHLBI definition is defined as having three or more of the following characteristics: (1) systolic blood pressure 130 mm Hg or diastolic blood pressure 85 mm Hg, (2) fasting glucose 100 mg/
dl, (3) triglycerides 150 mg/dl, (4) HDL cholesterol <40 mg/dl for men or <50 mg/dl for women, or (5) waist circumference 102 cm for men or 88 cm for women.
CI, confidence interval; SE, standard error.
b

a

73.0 (0.4)
47.9 (0.5)
262.8 (35.7)
102.4 (0.8)
14.5 (0.3)
75.3 (0.4)
54.9 (0.6)
203.5 (31.1)
101.1 (1.3)
14.2 (0.2)
73.9
50.6
252.5
99.5
14.3

(0.2)
(0.4)
(31.0)
(0.5)
(0.2)

(0.2)
(0.5)
(34.9)
(0.7)
(0.2)

(0.3)
(0.5)
(33.2)
(0.5)
(0.3)
73.8
50.2
258.7
99.1
14.2
71.5
55.2
212.6
96.6
14.3
76.4 (0.4)
45.7 (0.5)
294.8 (39.4)
102.6 (0.6)
14.2 (0.2)

92.2 (0.5)
118.8 (0.5)
92.1 (0.4)
122.6 (0.7)
91.1 (0.4)
120.8 (0.5)
87.7 (0.5)
118.2 (0.6)

Waist circumference (cm)
Systolic blood pressure
(mm Hg)
Diastolic blood pressure (mm Hg)
HDL cholesterol (mg/dl)
Triglycerides (mg/dl)
Plasma glucose (mg/dl)
Person-years of follow-up

91.3 (0.3)
120.9 (0.4)

95.1 (0.4)
123.8 (0.5)

Mexican-American,
mean (SE)
Non-Hispanic Black,
mean (SE)
Non-Hispanic White,
mean (SE)
Women,
mean (SE)
Men,
mean (SE)
All,
mean (SE)
TABLE 1. (continued).
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Comparison between models using the harmonized MetS definition,
number of abnormal components, and metabolic score were based
on predictability of the models from concordance analysis (Harrell’s
C coefficient and Gonen and Heller’s K coefficient) and goodnessof-fit (Akaike Information Criterion, Bayesian Information Criterion,
and Royston’s R2). These models were also tested against a model
having all the MetS components in the model as continuous variables. All analyses were performed using STATA 13.0 (StataCorp
LP, College Station, TX).

Results
Demographic, anthropometric, and laboratory characteristic by gender and race/ethnicity are presented in Table 1. Women had an older
age distribution than men with 15% being 65 years or older compared
with 11% of men. Mexican-Americans were a younger group with
76% between the ages of 18 and 44 years compared with AfricanAmericans (69%) and non-Hispanic whites (57%). About 47% of
men and 43% of women had some college education or college
degree. Education varied between race/ethnic groups with 18% of
Mexican-Americans, 34% of African-Americans, and 48% of nonHispanic whites with some college education or college degree attainment. The prevalence of MetS did not greatly vary by gender, but
there was some variability among race/ethnic groups with 22% of
non-Hispanic blacks meeting harmonized MetS compared with 28%
non-Hispanic whites and 31% of Mexican-Americans. Person-time of
follow-up was similar between gender and race/ethnic groups.
Systolic blood pressure, diastolic blood pressure and triglycerides
were independently associated with CVD mortality in non-Hispanic
white men (Table 2). In these associations, the strength of association
was greatest for systolic blood pressure (adjusted standardized hazard
ratio 5 1.51, 95% confidence interval: 1.06-2.16) and diastolic blood
pressure (1.51, 1.10-2.07) compared with triglycerides (1.16, 1.131.19). Among non-Hispanic black men, systolic (1.58, 1.17-2.13) and
diastolic (1.53, 1.21-1.93) blood pressures as well as HDL cholesterol (1.43, 1.14-1.79) were independently associated with CVD mortality. None of the metabolic components were independently associated with CVD mortality among Mexican-American men.
Systolic blood pressure was associated with CVD mortality within
all race/ethnic groups in women and the strongest association was
observed among Mexican-American (1.97, 1.20-3.23) compared
with non-Hispanic whites (1.43, 1.22-1.68) and non-Hispanic blacks
(1.44, 1.18-1.75) (Table 2, unadjusted estimates Supporting Information Table S1). Diastolic blood pressure was associated with CVD
mortality among all women (1.24, 1.02-1.51). Other significant independent association with CVD mortality was fasting glucose (1.68,
1.40-2.01) in Mexican-American women.
There was slight variation in the standardized factor loadings from
the structural equation modeling by gender and race/ethnicity (Figure 1). Based on the Score and Wald tests (Supporting Information
Table S2), factor loadings in the path diagrams were significantly
different across gender and race groups. Overall, the standardized
factor loadings were greatest for waist circumference (ranging from
0.58 to 0.81) for all subgroups. In men, standardized factor loading
absolute values for all other metabolic components were close to
half that of waist circumference, with HDL having a negative value.

www.obesityjournal.org
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TABLE 2 Cox proportional hazard ratio for CVD mortality associated with each standardizeda metabolic component
individually by gender—National Health and Nutrition Examination Survey III, United States

Men

All
Waist circumference
Systolic blood pressure
Diastolic blood pressure
HDL cholesterol
Triglycerides
Plasma glucose
Non-Hispanic white
Waist circumference
Systolic blood pressure
Diastolic blood pressure
HDL cholesterol
Triglycerides
Plasma glucose
Non-Hispanic black
Waist circumference
Systolic blood pressure
Diastolic blood pressure
HDL cholesterol
Triglycerides
Plasma glucose
Mexican-American
Waist circumference
Systolic blood pressure
Diastolic blood pressure
HDL cholesterol
Triglycerides
Plasma glucose

N

No.
events

2721

220

1126

762

833

Women

HRb

95% CI

P

1.02
1.50
1.48
1.09
1.15
1.03

(0.779-1.344)
(1.141-1.961)
(1.155-1.897)
(0.827-1.435)
(1.122-1.168)
(0.796-1.326)

0.870
0.004
0.002
0.542
<0.0001
0.834

1.06
1.51
1.51
1.01
1.16
0.97

(0.759-1.474)
(1.060-2.155)
(1.096-2.072)
(0.728-1.414)
(1.129-1.186)
(0.656-1.443)

0.740
0.023
0.012
0.933
<0.0001
0.891

0.88
1.58
1.53
1.43
0.73
1.11

(0.601-1.299)
(1.166-2.131)
(1.212-1.930)
(1.137-1.786)
(0.413-1.280)
(0.938-1.306)

0.529
0.003
0.0004
0.002
0.270
0.228

1.01
1.61
1.13
0.86
1.32
1.15

(0.535-1.906)
(0.901-2.859)
(0.739-1.716)
(0.391-1.888)
(0.907-1.913)
(0.793-1.665)

0.975
0.108
0.581
0.706
0.148
0.462

122

N

No.
events

3038

203

1318

55

902

43

818

HRb

95% CI

P

1.14
1.44
1.24
1.01
1.18
1.09

(0.937-1.389)
(1.268-1.630)
(1.024-1.510)
(0.765-1.334)
(0.951-1.454)
(0.872-1.358)

0.189
<0.0001
0.028
0.944
0.134
0.455

1.10
1.43
1.23
1.03
1.19
1.12

(0.875-1.390)
(1.221-1.680)
(0.962-1.572)
(0.743-1.428)
(0.938-1.510)
(0.892-1.418)

0.406
<0.0001
0.099
0.859
0.153
0.321

1.29
1.44
1.26
0.90
1.46
0.92

(0.919-1.803)
(1.177-1.753)
(0.951-1.658)
(0.634-1.288)
(0.927-2.290)
(0.701-1.195)

0.141
0.0004
0.108
0.575
0.103
0.516

1.36
1.97
1.67
0.87
1.15
1.68

(0.807-2.282)
(1.203-3.228)
(0.799-3.494)
(0.569-1.329)
(0.763-1.726)
(1.404-2.014)

0.249
0.007
0.173
0.519
0.508
<0.0001

125

54

24

Each hazard ratio is a model.
a
All metabolic components were standardized to the normal distribution (mean 5 0 and standard deviation 5 1) for the purpose of coefficient comparison across models.
b
Models adjusted for age, smoking status, education, physical activity, alcohol consumption, and medication use for diabetes, hypertension, or high cholesterol.
HR, hazard ratio; CI, confidence interval.

The greatest variation in factor loadings across race/ethnic groups in
men was between systolic (ranging from 0.34 to 0.43) and diastolic
(ranging from 0.25 to 0.57) blood pressures. In women, standardized
factor loadings for metabolic components varied more across race/
ethnic groups compared with men with the largest range observed
for waist circumference (0.58-0.80). Standardized factor loadings
estimated without correlated errors for SBP and DBP as well as
HDL and TG are shown on Supporting Information Figure S1. Since
estimated covariance between SBP and DBP as well as HDL and
TG were significantly different than zero (P value <0.05, and in
most cases P value <0.001), all further results only considered
MetS score derived from the path diagrams with specified correlated
error. Based on the SRMR and CD, all path diagrams had good fit.
The metabolic score derived from the structural equation modeling
was associated with CVD mortality for: non-Hispanic white women
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(1.29, 1.01-1.64), non-Hispanic black women (2.03, 1.12-3.69), and
Mexican-American women (3.57, 2.21-5.76) (Table 3, unadjusted
estimates Supporting Information Table S3). In this study, the
harmonized defined MetS (yes/no) was not significantly associated
with CVD mortality in almost all of the gender and race/ethnic subgroups with the exception among non-Hispanic black women (2.69,
1.45-4.97). The number of abnormal metabolic components present
based on the harmonized definition was associated with CVD mortality for: non-Hispanic white women (1.15, 1.04-1.27), nonHispanic black women (1.40, 1.10-1.77), and Mexican-American
women (1.32, 1.07-1.61). When comparing the models using the
metabolic score with those using harmonized MetS or the number of
abnormal metabolic components present, the models with the
metabolic score were a better fit based on the Akaike Information
Criterion and Bayesian Information Criterion. Using concordance
analysis, for the most part, the models with better predictability
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Figure 1 Metabolic score path diagrams with standardized factor loadings for each gender-race subgroup among US adults—National Health and Nutrition Examination Survey III, 1988–2006. WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; TG, triglycerides; FG, fasting glucose.

were those with the metabolic score based on the Harrell’s C
coefficient and G€onen and Heller’s K coefficient (Supporting Information Table S4). However, having all metabolic components as
continuous variables in the model had the best fit.

Discussion
SEM to examine the associations between MetS and cardiovascular
mortality has been sparsely utilized, yet it offers some advantages in
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assessing risk including considering actual values for each MetS
component, their collective association with cardiovascular risk, and
allowing the collective influence of MetS components to vary within
subgroups of race/ethnicity and gender. MetS conceptually has been
an information reduction approach in identifying those individuals at
greater risk for CVD mortality instead of considering all components
as predictors which resulted in the best fit and predictability model
(Supporting Information Table S4). However, among the three forms
of defining metabolic syndrome, the metabolic score estimated from
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TABLE 3 Cox proportional hazard ratioa for the association between metabolic syndrome (score and traditional definition) and
CVD mortality stratified by gender and race—National Health and Nutrition Examination Survey III, United States

Metabolic scoreb

Men
Non-Hispanic white
Non-Hispanic black
Mexican-American
Women
Non-Hispanic white
Non-Hispanic black
Mexican-American

No. metabolic
components

Metabolic syndrome

N

No. events

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

2721
1126
762
833
3038
1318
902
818

220
122
55
43
203
125
54
24

1.28
1.41
0.90
1.36
1.34
1.29
2.03
3.57

(0.961-1.701)
(0.978-2.023)
(0.617-1.323)
(0.726-2.544)
(1.059-1.683)
(1.009-1.644)
(1.116-3.689)
(2.209-5.759)

0.092
0.066
0.602
0.337
0.015
0.042
0.020
<0.0001

1.08
1.13
0.89
0.88
1.27
1.16
2.69
1.99

(0.780-1.491)
(0.758-1.674)
(0.491-1.616)
(0.372-2.067)
(0.899-1.806)
(0.782-1.708)
(1.453-4.969)
(0.691-5.705)

0.648
0.555
0.704
0.763
0.174
0.467
0.002
0.203

1.02
1.02
0.98
1.04
1.16
1.15
1.40
1.32

(0.884-1.181)
(0.856-1.226)
(0.777-1.243)
(0.725-1.485)
(1.056-1.276)
(1.036-1.267)
(1.103-1.766)
(1.072-1.613)

0.770
0.793
0.885
0.842
0.002
0.008
0.006
0.009

a

Models adjusted for age, smoking status, education, physical activity, alcohol consumption, and medication use for diabetes, hypertension, or high cholesterol.
Metabolic score used in the models was derived specifically for each individual subgroup.
HR, hazard ratio; CI, confidence interval.
b

SEM was a slightly better predictor for CVD mortality compared
with harmonized MetS or the number of metabolic components present in this study of a representative sample of US adults.
Of all the metabolic components, systolic and diastolic blood pressure measures were repeatedly independently associated with CVD
mortality across gender and race/ethnicity subgroups. Even though
systolic blood pressure and diastolic blood pressure were associated
with CVD mortality in this study, it is an association previously
documented in other studies (16-18). Although it has been previously recognized that waist circumference (19-21), triglycerides
(22), and fasting glucose (23) are independently associated with
CVD risk; these findings were not consistent in this study. There
were no significant associations observed with waist circumference
and CVD mortality. Several significant linear associations with
CVD mortality were observed within selected groups, including:
fasting glucose among Mexican-American women, triglycerides
among non-Hispanic white men, HDL cholesterol among nonHispanic black men, and blood pressure among all groups except
Mexican-American men. Dichotomizing these variables, as what is
done in the harmonized MetS, may lose the effectiveness of quantifying CVD risk.
Many studies have found MetS to be associated with CVD events
and/or mortality (13,24-32). Even though this association was not
observed in this study, some reasons for the discrepancy could be
due to the MetS definition used and the study population. Before the
release of the harmonized definition in 2009, all MetS studies varied
on the components and cut points used to define MetS relying on
definitions from the World Health Organization, European Group
for the Study of Insulin Resistance, National Cholesterol Education
Program, American College of Endocrinology, or International Diabetes Federation. Although systematic reviews and meta-analyses on
this topic have been consistent showing a positive association
between MetS and CVD (13,24-26,28,32), the findings between
studies were variable and the harmonized definition used in this
study has been reported to attenuate results more so than the other
definitions (11,12,27). Furthermore, some studies would substitute
certain measures for others based on the data collected, such as
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using body mass index as opposed to waist circumference. In addition, the majority of the studies that investigated the association
between MetS and CVD events or mortality were conducted among
populations outside of the US. The few studies from the US were
not very diverse or did not report results within gender or race/ethnic subgroups.
A major weakness of all the MetS definitions is that quantifying
CVD risk is limited to yes/no and differentiation of CVD risk
between combinations of components is ignored. Components may
not weigh equally towards CVD risk and different clusters of components may increase CVD risk more so than others (27,31). In a
study by Huang et al. (27), the cluster of high blood pressure, HDL,
and WC appeared to have the highest risk for CVD mortality of all
combinations, even compared with having all metabolic components
present. They also observed that having high blood pressure, HDL,
WC, and FG decreased the risk by half compared with if FG was
not in the cluster. The underlying etiology of how the components
interact to increase CVD risk is unknown. We do not fully understand the relationship all metabolic components have in relation to
CVD risk and two-way, three-way, four-way, or a five-way interaction between metabolic components may be present. As a result,
using harmonized MetS or treating metabolic components individually may not be the most effective way to assess or address CVD
risk, especially among certain subgroups or populations.
Previous studies using SEM to assess MetS with CVD risk have
found positive associations with atherosclerosis, coronary artery calcification, diabetes, carotid intima media thickness, and CVD mortality (33-37). Although gender and race/ethnicity subgroup differences in MetS using SEM has been noted (34,38,39); the previous
studies either did not consider these differences, examined different
path diagrams, or had study populations from other countries compared with this study. However, across all studies, the consensus
was that assessing MetS using SEM was more effective in estimating CVD risk than MetS (yes/no).
There are a few limitations in this study. First, the follow-up time is
based on linkage to death certificates from the National Death Index
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and it is possible that some deaths might have been missed. Second,
we were unable to capture CVD events; we only had data on CVD
mortality which limits our ability to assess the association with
MetS and overall CVD risk. Third, the structural equation model
proposed may not represent the true underlying etiology, especially
if there are interactions between components. We considered each
metabolic component acting independently although simultaneously
in contributing to the metabolic score, but we may need to consider
how the values of some components may affect the values of
another to further increase CVD risk. Additionally, the structural
equation model assumed a reflective approach implying that changes
in the latent variable, MetS score, affect each component as opposed
to the counterfactual formative approach inferring that changes in
the components affect the MetS score. Potential mis-specification of
the model approach can be problematic in determining which components load on a factor when performing traditional factor analysis
(40). However, in our study we did not conduct any exploratory
analysis to determine which variables to include as components of
the MetS score but tested a pre-specified structural equation model
based on predetermined risk factors and therefore potential misspecification of the model would not affect our results. Fourth,
although we were able to link to mortality data, all measured data
were of cross-sectional design and only obtained at baseline. Therefore, changes may have occurred during follow-up time that changed
CVD risk; such as initiation of medication use, diagnosis, or medical
procedures; could not be accounted for in this study. Fifth, many
statistical tests were performed and some significant results may
have occurred due to chance. Finally, significant differences in the
SEM analyses may have been a function of large sample sizes.
Future studies are needed to understand the etiology of metabolic
components and how they may interact or relate to CVD risk.
Although studies have shown CVD risk differences by gender and
by race, most studies do not show results within race-gender subcategories and there is a need for more research in this area. Another
research focus needed is investigations within subcategories of CVD
due to the heterogeneity of this category (e.g., stroke, heart attack,
or arrhythmia). Risk assessment using harmonized MetS may not
capture or distinguish risk severity for CVD mortality. Although it
has been previously stated that treatment for MetS is no different
than the treatment of each component (8) and it may be the best
current approach, treating individual risk factors independently may
not be the most effective treatment method due to possible interactions between components which may require consideration of the
relationship these factors have with each other. Other than diet and
physical activity which may affect all components, we recognize
that at this time treating each component individually and focusing
on prevention are the best practices available until more is learned
and the knowledge gap is narrowed. In this study, SEM to assess
CVD mortality risk provided additional information than harmonized
MetS or the number of MetS components present in that predictions
became significant when using the metabolic score. Although the
metabolic score driven from SEM has the potential to accurately
estimate CVD risk tailored for different subgroups and therefore
have positive clinical and public health implications, at this time
more knowledge is needed on the etiology between metabolic components and CVD risk to establish the true path diagram and may
be the reason that the models with all the components present predicted CVD mortality better than any of the MetS approaches. Even
though calculations of the metabolic score using SEM is complex
posing impractical risk assessment ability in the clinical setting, the
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future of electronic medical records may be able to take the actual
metabolic component values and estimate more accurate CVD risk
tailored for certain subgroups.O
C 2015 The Obesity Society
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Table S1. Unadjusted Cox Proportional Hazard Ratio for Cardiovascular Disease Mortality associated with each STANDARDIZEDa
metabolic component by gender- National Health and Nutrition Examination Survey III, United States
Men
Women
# of
# of
N
HRb
95% CI
P-value
N
HRb
95% CI
P-value
events
events
2721
220
3038
203
All
Waist circumference
1.12
(0.852, 1.473)
0.418
1.23
(1.015, 1.499)
Systolic blood pressure
1.53
(1.142, 2.045)
0.004
1.41
(1.226, 1.621)
Diastolic blood pressure
1.41
(1.117, 1.783)
0.004
1.28
(1.062, 1.533)
HDL cholesterol
0.95
(0.689, 1.315)
0.765
1.02
(0.788, 1.327)
Triglycerides
1.12
(1.104, 1.133)
0.000
1.21
(1.000, 1.465)
Plasma glucose
1.16
(0.986, 1.370)
0.074
1.12
(0.978, 1.281)
1126
122
1318
125
Non-Hispanic white
Waist circumference
1.22
(0.894, 1.672)
0.208
1.19
(0.945, 1.496)
Systolic blood pressure
1.53
(1.049, 2.237)
0.027
1.35
(1.150, 1.592)
Diastolic blood pressure
1.41
(1.059, 1.876)
0.019
1.25
(1.014, 1.535)
HDL cholesterol
0.81
(0.542, 1.196)
0.283
1.04
(0.776, 1.398)
Triglycerides
1.13
(1.109, 1.142)
0.000
1.23
(0.998, 1.524)
Plasma glucose
1.15
(0.931, 1.421)
0.193
1.13
(0.959, 1.325)
762
55
902
54
Non-Hispanic black
Waist circumference
0.89
(0.620, 1.265)
0.504
1.39
(1.012, 1.919)
Systolic blood pressure
1.52
(1.127, 2.047)
0.006
1.52
(1.265, 1.817)
Diastolic blood pressure
1.53
(1.212, 1.924)
0.000
1.29
(1.022, 1.638)
HDL cholesterol
1.31
(1.040, 1.657)
0.022
0.92
(0.669, 1.271)
Triglycerides
0.80
(0.453, 1.400)
0.429
1.41
(0.909, 2.179)
Plasma glucose
1.20
(1.037, 1.392)
0.015
1.02
(0.887, 1.180)
833
43
818
24
Mexican-American
Waist circumference
0.81
(0.425, 1.524)
0.505
1.52
(0.978, 2.351)
Systolic blood pressure
1.39
(0.830, 2.324)
0.211
2.22
(1.343, 3.684)
Diastolic blood pressure
0.97
(0.693, 1.344)
0.835
1.51
(0.667, 3.415)
HDL cholesterol
0.81
(0.353, 1.850)
0.614
0.74
(0.489, 1.111)
Triglycerides
1.32
(0.924, 1.895)
0.127
1.16
(0.836, 1.604)
Plasma glucose
1.09
(0.793, 1.501)
0.594
1.38
(1.129, 1.678)
Abbreviations: HR, hazard ratio; CI, confidence interval
a
All metabolic components were standardized to the normal distribution for the purpose of coefficient comparison across models.
b
Models adjusted for age.

0.035
0.000
0.009
0.867
0.050
0.101
0.140
0.000
0.037
0.786
0.053
0.147
0.042
0.000
0.032
0.620
0.125
0.751
0.063
0.002
0.323
0.145
0.378
0.002

Table S2. P-values for testing differences in structural equation models by gender and race
Men
Women
Gender
Race
Race
Race
Score
Wald
Score
Wald
Score
Wald
Score
Wald
Testa
Testb
Testa
Testb
Testa
Testb
Testa
Testb
<0.0001
<0.0001
0.015
<0.0001
0.658
0.0016
0.0001
<0.0001
Waist circumference
<0.0001
<0.0001
0.012
<0.0001
0.338
0.0010
0.110
0.0001
Systolic blood pressure
0.732
0.040
<0.0001
<0.0001
<0.0001
<0.0001
0.006
<0.0001
Diastolic blood pressure
0.018
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.003
<0.0001
HDL cholesterol
<0.0001
<0.0001
0.001
<0.0001
0.415
<0.0001
<0.0001
<0.0001
Triglycerides
0.043
0.012
<0.0001
<0.0001
0.394
<0.0001
<0.0001
<0.0001
Fasting glucose
NOTE: Testing differences in structural equation models could not be performed in the survey setting. Therefore, these results do not
consider sampling design or weights.
a
Score test reported for testing difference in factor loadings across groups. The null hypothesis is that the factor loadings are equal.
b
Wald test reported for testing difference in the variance for parameters across groups. The null hypothesis is that the variance is equal across
groups.

Table S3. Unadjusted Cox proportional hazard ratioa for the association between Metabolic syndrome (score and traditional definition) and CVD mortality
stratified by gender and race – National Health and Nutrition Examination Survey III, United States
N

# of events

2721
1126
762
833

220
122
55
43

P-value
0.002
0.0002
0.845
0.839

HR
1.35
1.50
0.93
0.75

3038
203
1.40
(1.143, 1.714)
0.001
Women
Non-Hispanic white
1318
125
1.33
(1.081, 1.644)
0.007
Non-Hispanic black
902
54
2.03
(1.304, 3.163)
0.002
Mexican-American
818
24
2.44
(1.684, 3.523)
<0.0001
Abbreviations: HR, hazard ratio; CI, confidence interval
a
Models adjusted for age.
b
Metabolic score used in the models were derived specifically for each individual subgroup.

1.46
1.34
2.51
2.33

Men
Non-Hispanic white
Non-Hispanic black
Mexican-American

HR
1.43
1.61
0.97
1.06

Metabolic Scoreb
95% CI
(1.140, 1.801)
(1.254, 2.064)
(0.672, 1.384)
(0.602, 1.870)

Metabolic Syndrome
95% CI
P-value
(0.979, 1.859)
0.067
(1.033, 2.169)
0.033
(0.517, 1.668)
0.804
(0.313, 1.782)
0.511
(1.067, 1.988)
(0.963, 1.873)
(1.467, 4.300)
(0.733, 7.383)

0.018
0.082
0.001
0.152

# of Metabolic Components
HR
95% CI
P-value
1.13
(0.986, 1.298)
0.079
1.16
(0.994, 1.359)
0.060
1.06
(0.858, 1.316)
0.578
0.98
(0.712, 1.336)
0.876
1.20
1.19
1.37
1.34

(1.103, 1.314)
(1.086, 1.299)
(1.141, 1.646)
(1.085, 1.658)

<0.0001
0.0002
0.001
0.007

Table S4. Goodness-of-fit and Predictability Results for the Comparison Between Models Using Metabolic Score, Metabolic
Syndrome, or Number of Metabolic Components by Gender-Race Subgroups
Metabolic Score
Metabolic Syndrome Prevalence
C
K
R
C
K
R
AIC
BIC
AIC
BIC
statistic statistic square
statistic statistic square
Men
Non-Hispanic white
578.58 623.81
0.881
0.848
0.561
581.24 626.48
0.881
0.847
0.553
Non-Hispanic black
442.48 484.21
0.865
0.799
0.692
442.71 484.43
0.864
0.802
0.691
Mexican-American
253.32 295.85
0.875
0.806
0.558
253.44 295.97
0.872
0.800
0.557
Women
Non-Hispanic white
723.51 770.16
0.915
0.868
0.716
725.38 772.03
0.915
0.866
0.712
Non-Hispanic black
465.18 508.42
0.912
0.819
0.898
463.83 507.07
0.912
0.809
0.900
Mexican-American
140.55 178.20
0.922
0.842
0.800
151.40 193.76
0.916
0.829
0.720
# of Metabolic Components
All components in model
C
K
R
C
K
R
AIC
BIC
AIC
BIC
statistic statistic square
statistic statistic square
Men
Non-Hispanic white
581.33 626.57
0.881
0.847
0.553
366.74 433.17
0.888
0.851
0.576
Non-Hispanic black
442.80 484.52
0.864
0.802
0.690
355.26 417.09
0.899
0.815
0.805
Mexican-American
253.63 296.16
0.872
0.799
0.556
195.37 257.12
0.881
0.795
0.614
Women
Non-Hispanic white
723.74 770.39
0.916
0.868
0.716
478.31 547.49
0.928
0.873
0.764
Non-Hispanic black
466.69 509.93
0.908
0.810
0.895
315.56 379.19
0.921
0.817
0.920
Mexican-American
150.97 193.33
0.917
0.829
0.725
93.38 154.54
0.925
0.852
0.883
AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion; C statistic, Harrell’s C-coefficient; K statistic, Gönen and
Heller’s K-coefficient; R square, Royston’s R-square
For both AIC and BIC, smaller number is a better fit.
For R-square, C- and K- statistics, the larger number is a better predictor.
All components in the model include: waist circumference, systolic blood pressure, diastolic blood pressure, HDL cholesterol,
triglycerides, and fasting glucose as proxy for metabolic syndrome along with

Supplemental Figure 1. Metabolic Score Path Diagrams with Standardized Factor Loadings for
Each Gender-Race Subgroup without Correlated Errors
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